Drug profile · INN
rimonabant
ZIMULTI
rimonabant (ZIMULTI) is a cannabinoid cb1 receptor antagonist.
EMA: withdrawn Alimentary tract and metabolism (A08) A08AX01
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — rimonabant
- Class
- Alimentary tract and metabolism (A08)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
rimonabant (ZIMULTI) is a cannabinoid cb1 receptor antagonist.
Key facts
INN rimonabant
Brand ZIMULTI
Mechanism Cannabinoid CB1 receptor antagonist
Target Cannabinoid receptor 1
Therapeutic class Alimentary tract and metabolism (A08)
ATC code A08AX01
Mechanism of action
Cannabinoid CB1 receptor antagonist
Primary target: Cannabinoid receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rimonabant?
rimonabant (ZIMULTI) is a cannabinoid cb1 receptor antagonist.
What is the brand name for rimonabant?
ZIMULTI is a marketed brand name for rimonabant. Check FDA Drugs@FDA for the current US label holder and prescribing information.